Cerebral palsy and bisphosphonates - and what can be learned from other types of secondary osteoporosis in children: A scoping review.
bisphosphonate
bone mineral density
cerebral palsy
children
secondary osteoporosis
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
11
01
2023
received:
05
09
2022
accepted:
13
01
2023
pubmed:
17
1
2023
medline:
15
3
2023
entrez:
16
1
2023
Statut:
ppublish
Résumé
We aimed to improve bone health management of children with cerebral palsy (CP) by reviewing studies investigating bisphosphonate therapy in children with CP and other types of secondary osteoporosis. We included trials on bisphosphonate treatment reporting any direct bone measurement or fracture outcome. All studies of patients with CP were included. We also included all controlled trials of children with secondary bone fragility as well as observational studies with ≥20 participants or at least 3 years of follow-up. Studies were assessed according to PRISMA guidelines using the RoB2-tool and the Newcastle-Ottawa Scale. We reviewed 1104 studies and found 37 eligible. Some studies were sufficiently homogeneous to include in a meta-analysis, and we found a 1-year effect on lumbar spine bone mineral density (BMD) Z-score of +0.65 after oral and + 1.21 after intravenous bisphosphonates in children with secondary osteoporosis. Further, data on adverse events and post-treatment follow-up were reviewed. Limitations were heterogeneity and small size of the included studies. Meta-analysis consistently showed significant BMD increases with bisphosphonates in children with secondary osteoporosis. Direct evidence of the effect of bisphosphonates on reducing fractures is lacking. We found no reports of long-term adverse events yet longer studies are needed.
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-629Subventions
Organisme : Aarhus Universitets Forskningsfond
Organisme : Health Research Fund of Central Denmark Region
Organisme : Medicin Fund of the Danish Regions
Organisme : Regionshospitalet Randers
Informations de copyright
© 2023 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.
Références
Presedo A, Dabney KW, Miller F. Fractures in patients with cerebral palsy. J Pediatr Orthop. 2007;27(2):147-153.
Uddenfeldt Wort U, Nordmark E, Wagner P, Düppe H, Westbom L. Fractures in children with cerebral palsy: a total population study. Dev Med Child Neurol. 2013;55(9):821-826.
Leet AI, Mesfin A, Pichard C, et al. Fractures in children with cerebral palsy. J Pediatr Orthop. 2006;26:624-627.
Ozel S, Switzer L, Macintosh A, Fehlings D. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update. Dev Med Child Neurol. 2016;58(9):918-923.
Simm PJ, Biggin A, Zacharin MR, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018;54(3):223-233.
Galindo-Zavala R, Bou-Torrent R, Magallares-López B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol. 2020;18(1):1-14.
Novak I, McIntyre S, Morgan C, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55(10):885-910.
Bouxsein ML, Eastell R, Lui LYY, et al. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res. 2019;34(4):632-642.
Henderson RC, Berglund LM, May R, et al. The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy. J Bone Miner Res. 2010;25(3):520-526.
Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80-100.
Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab. 2005;90(7):4051-4056.
Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85(6):1052-1062.
Kim MJ, Kim SN, Lee IS, et al. Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis. J Pediatr Endocrinol Metab. 2015;28(11-12):1343-1350.
Fehlings D, Switzer L, Agarwal P, et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Dev Med Child Neurol. 2012;54(2):106-116.
Hurley T, Zareen Z, Stewart P, McDonnell C, McDonald D, Molloy E. Bisphosphonate use in children with cerebral palsy. Cochrane Database Syst Rev. 2021;(7):CD012756.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]; 2011.
Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;(4):CD005324.
Zareen Z, Mcdonnell C, Mc Donald D, Molloy E. Bisphosphonate use in children with cerebral palsy. Cochrane Database Syst Rev. 2017;(8):CD012756.
Covidence Veritas Health Innovation. Covidence systematic review sofware; 2020. Accessed January 14, 2020. https://www.covidence.org
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Accessed April 25, 2016. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.
Harris PA, Taylor R, Minor BL, et al. The REDCap Consortium: Building An International Community of Software Platform Partners. Vol 95. Academic Press Inc; 2019.
Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002;141(5):644-651.
Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT. Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol. 2005;35(5):511-517.
Bachrach SJ, Kecskemethy HH, Harcke HT, Lark RK, Miller F, Henderson RC. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy. J Clin Densitom. 2006;9(2):167-174.
Bachrach SJ, Kecskemethy HH, Harcke HT, Hossain JR. Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. Dev Med Child Neurol. 2010;52(9):837-842.
Dominguez-Bartmess SN, Tandberg D, Cheema AM, Szalay EA. Efficacy of alendronate in the treatment of low bone density in the pediatric and young adult population. J Bone Joint Surg Am. 2012;307(20):e621-e626.
Hobby BD, Dominguez-Bartmess S, Szalay EA, et al. Prevention of postoperative osteopenia using IV pamidronate: a pilot study. J Pediatr Orthop. 2013;33(7):763-767.
Lambert AS, Rothenbuhler A, Charles P, et al. Lower incidence of fracture after IV bisphosphonates in girls with Rett syndrome and severe bone fragility. PLoS One. 2017;12(10):e0186941.
Sees JP, Sitoula P, Dabney K, et al. Pamidronate treatment to prevent reoccurring fractures in children with cerebral palsy. J Pediatr Orthop. 2016;36(2):193-197.
Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol. 2006;48(9):709-712.
Rooney M, Bishop N, Davidson J, et al. The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: a randomised double-blind controlled trial. EClinicalMedicine. 2019;12:79-87.
Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology. 2005;44(6):813-818.
Golden NH, Iglesias EA, Jacobson MS, et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2005;90(6):3179-3185.
El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant. 2004;8(4):357-361.
Bianchi ML, Colombo C, Assael BM, et al. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. Lancet Respir Med. 2013;1(5):377-385.
Jacobson DL, Lindsey JC, Gordon C, et al. Alendronate improves bone mineral density in children and adolescents perinatally infected with human immunodeficiency virus with low bone mineral density for age. Clin Infect Dis. 2020;71(5):1281-1288.
Lindsey JC, Jacobson DL, Spiegel H, et al. Safety and efficacy of 48 and 96 weeks of alendronate in children and adolescents with perinatal human immunodeficiency virus infection and low bone mineral density for age. Clin Infect Dis. 2020;72(6):1059-1063.
Paksu MS, Vurucu S, Karaoglu A, et al. Osteopenia in children with cerebral palsy can be treated with oral alendronate. Childs Nerv Syst. 2012;28(2):283-286.
Cohran V, Cassedy A, Hawkins A, Bean J, Heubi J. Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial. J Pediatr Rehabil Med. 2013;6(2):85-93.
Grenda R, Karczmarewicz E, Rubik J, et al. Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients - a prospective study. Pediatr Transplant. 2011;15(2):205-213.
Acott PD, Wong JA, Lang BA, Crocker JFS. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol. 2005;20(3):368-373.
Klein GL, Wimalawansa SJ, Kulkarni G, Sherrard DJ, Sanford AP, Herndon DN. The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study. Osteoporos Int. 2005;16(6):631-635.
Przkora R, Herndon DN, Sherrard DJ, Chinkes DL, Klein GL. Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury. Bone. 2007;41(2):297-302.
Sbrocchi AM, Forget S, Laforte D, Azouz EM, Rodd C. Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatr Int. 2010;52(5):754-761.
Simm PJ, Johannesen J, Briody J, et al. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis. Bone. 2011;49(5):939-943.
Ooi HL, Briody J, Biggin A, Cowell CT, Munns CF. Intravenous zoledronic acid given every 6 months in childhood osteoporosis. Horm Res Paediatr. 2013;80(3):179-184.
Durkin K, Shepherd K, Alexy E, Noritz G. Effects of zoledronic acid on children and young adults with low bone mineral density. Dev Med Child Neurol. 2018;60:70-71.
Wiedemann A, Renard E, Hernandez M, et al. Annual injection of Zoledronic acid improves bone status in children with cerebral palsy and Rett syndrome. Calcif Tissue Int. 2019;104(4):355-363.
Nasomyont N, Hornung LN, Gordon CM, Wasserman H. Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review. Bone. 2019;121:60-67.
Valiyeva S, Alexeeva E, Bzarova T, et al. The efficacy and safety of ibandronic acid for intravenous administration for treatment of severe systemic osteoporosis in patients with juvenile arthritis. Ann Rheum Dis. 2013;23:S569.
Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Ltd; 2019:1-694.
Nasomyont N, Hornung LN, Wasserman H. Intravenous bisphosphonate therapy in children with spinal muscular atrophy. Osteoporos Int. 2020;31(5):995-1000.
Unal E, Abaci A, Bober E, Buyukgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab. 2006;19(4):523-528.
Moon SJ, An YM, Kim SK, Kwon YS, Lee JE. The effect of low-dose intravenous bisphosphonate treatment on osteoporosis in children with quadriplegic cerebral palsy. Korean J Pediatr. 2017;60(12):403-407.
Martínez de Zabarte Fernández JM, Ros Arnal I, Peña Segura JL, García Romero R, Rodríguez Martínez G. Bone health impairment in patients with cerebral palsy. Arch Osteoporos. 2020;15(1):91.
Whitney DG, Caird MS, Jepsen KJ, Hurvitz EA, Hirth RA. Excess healthcare spending associated with fractures among adults with cerebral palsy. Published Online. 2022;15:101315.
Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of Zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2015;30(5):934-944.
Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2012;27(2):243-254.
Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938.
Whitney DG, Bell S, Hurvitz EA, Peterson MD, Caird MS, Jepsen KJ. The mortality burden of non-trauma fracture for adults with cerebral palsy. Bone Reports. 2020;13:100725.